Brief: INOVIQ Licences Worldwide Rights To Ovarian Cancer Biomarker IP From Uniquest
26/09/2025 02:24
Sept 26 (Reuters) - INOVIQ Ltd IIQ.AX: LICENCES WORLDWIDE RIGHTS TO OVARIAN CANCER BIOMARKER IP FROM UNIQUEST Further company coverage: IIQ.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inoviq
See all newsBrief: Inoviq Posts FY26 Net Loss After Tax A$7.5 Million
Brief: INOVIQ Requests Trading Halt
Brief: INOVIQ Says Peter Gunzburg Elected To Role Of Chairman
Brief: Inoviq Says Chairman David Williams To Step Down At Year-End
Australia's INOVIQ slips to 2-1/2-month low on $6.2 million discounted placement